Stocks and Investing Stocks and Investing
Wed, August 10, 2022

Mark Breidenbach Maintained (SYRS) at Buy with Decreased Target to $30 on, Aug 10th, 2022


Published on 2024-10-27 22:33:57 - WOPRAI, Mark Breidenbach
  Print publication without navigation


Mark Breidenbach of Oppenheimer, Maintained "Syros Pharmaceuticals, Inc." (SYRS) at Buy with Decreased Target from $90 to $30 on, Aug 10th, 2022.

Mark has made no other calls on SYRS in the last 4 months.



There are 2 other peers that have a rating on SYRS. Out of the 2 peers that are also analyzing SYRS, 0 agree with Mark's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Mark


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $60 on, Tuesday, July 12th, 2022
  • Matt Cross of "Alliance Global Partners" Maintained at Strong Buy with Decreased Target to $100 on, Tuesday, May 17th, 2022
Contributing Sources